Moreno, AA, Presas-Rodríguez, S, Gonzalez-Garcia, AM, Teniente-Sera, A, Martínez-Cáceres, EM, Querol, L, Martín-Aguilar, L, Meca-Lallana, JE, Dos Santos, CE, Millán, J, López, GV, Orgaz, ATC, Ruiz, VC, Anunciación, BAJ, Hervas, JV, Ruiz, LB, Bravo, GCA, Ramo, C. Monitoring Patients with Relapsing-Remitting Multiple Sclerosis Switching from Intravenous to Subcutaneous Natalizumab every 4 Weeks vs every 6 Weeks. Multiple Sclerosis Journal. 2025; 31(3)DOI:. PMID:. IF:5.000(Q1/2D).

Luce, L, Kocak, G, Alonso-Pérez, J, Straub,, Töpf, A, Díaz-Manera, J. Cracking the code: genotype-phenotype correlation models in sarcoglycanopathies. NEUROMUSCULAR DISORDERS. 2025; 53DOI:. PMID:. IF:2.800(Q2/5D).

Unoje, O, Hussain, Y, Habib, A, Claeys, K, Gwathmey, K, Sahagian, G, Cortés-Vicente, E, Liu, L, Jimenez, R, Patel, M, Masschaele, D, Mantegazza, R, Meisel, A, Seth, A, Attarian, S. Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT. ANNALS OF NEUROLOGY. 2025; 98DOI:. PMID:. IF:7.700(Q1/1D).

Forcadell-Díez, L, Pérez, G, Fernández, A, Puig-Barrachina, V, Subirats, IG, Cortés, E, Moral, PD, Juárez, O. HOW TO PROMOTE HEALTHY AND EQUITABLE RELATIONSHIPS IN FORMAL EDUCATION: THEORETICAL FRAMEWORK AND EDUCATIONAL PROPOSAL. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).

Bioque, M, Llorca-Bofi, V, MacDowell, KS, Amoretti, S, Mezquida, G, Cuesta, MJ, Diaz-Caneja, CM, Ibáñez, A, Segarra, R, González-Pinto, A, Roldán, A, Sáiz, PA, Mané, A, Lobo, A, Martínez-Pinteño, A, Cano-Escalera, G, Berrocoso, E, Bernardo, M. Impact of Relapse in BDNF Receptors Expression in Patients With a First Episode of Schizophrenia. SCHIZOPHRENIA BULLETIN. 2025; 51(5)DOI:10.1093/schbul/sbaf012. PMID:39977257. IF:4.800(Q1/2D).

March-Yagüe, A, Toledo, D, Díaz, A, Godoy, P, Pérez-Martinez, O, Pericas, C, Sánchez-Migallón, A, Domínguez, A. MPOX IN PEOPLE WITH HIV AND PREP USERS DURING THE 2022 OUTBREAK, SPAIN. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).